Overview

AGN-242428 in the Treatment of Plaque Psoriasis

Status:
Terminated

Trial end date:
2018-04-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of AGN-242428 in adult participants with moderate to severe plaque-type psoriasis.

Phase:

Phase 2

Details

Lead Sponsor:

Vitae Pharmaceuticals Inc., an Allergan affiliate
Vitae Pharmaceuticals, Inc.